Xeltis is pioneering a transformative approach to vascular implants through its proprietary Endogenous Tissue Restoration (ETR) platform. This innovative technology enables the gradual replacement of artificial vessels and valves with the patient's own living tissue, significantly reducing the risks associated with traditional implants, such as thrombosis, stenosis, calcification, and infection. The foundation of Xeltis' technology is rooted in Nobel prize-winning advancements in polymer science, specifically utilizing supramolecular chemistry to create nanofiber-based implants. These implants not only restore vascular function but also promote natural healing, as evidenced by extensive preclinical and clinical research demonstrating low infection rates and the absence of narrowing in the treated vessels.

The applications of Xeltis' ETR technology are broad, targeting critical areas in vascular surgery, including hemodialysis access and coronary arterial bypass surgery. The company aims to enhance patient care by providing self-healing, non-immunogenic implants that minimize the need for surgical reinterventions and maintain patency over time. With a focus on addressing unmet medical needs, Xeltis is committed to improving outcomes for patients worldwide, leveraging its advanced research and clinical expertise to deliver innovative solutions in vascular and valve replacement therapies.

Switzerland

Xeltis is developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue.

www.xeltis.com


Xeltis

Company Details